Transcode Therapeutics (RNAZ) Total Debt (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Total Debt came in at $652411.0 in Q2 2026, up 1728.25% quarter-over-quarter from $35685.0 in Q4 2021.
Powered by 
Analysis
Transcode Therapeutics (RNAZ) Total Debt (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has reported Total Debt for 3 consecutive years, with $652411.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Debt changed N/A year-over-year to $652411.0; the trailing twelve-month figure through Jun 2026 stood at $652411.0 (changed N/A YoY), and the FY2021 full-year result was $35685.0, changed 0.0% from the prior year.
- Total Debt grew to $652411.0 in Q2 2026 per RNAZ's latest filing, from $35685.0 in the prior quarter.
- Across five years, Total Debt topped out at $652411.0 in Q2 2026 and bottomed at $652411.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 62.75 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 28.66 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 8.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Transcode Therapeutics | 1.63 Mn | 1.63 Mn | - | 652,411.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 652,411.00 |
| Dec 31, 2021 | 35,685.00 |
| Jun 30, 2021 | 35,525.00 |
| Dec 31, 2020 | 35,685.00 |